Hims & Hers Health stock returns 31.83% annually over 5 years

0 min read     Updated on 22 Jul 2026, 03:54 AM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Hims & Hers Health has delivered an average annual return of 31.83% over the past five years, outperforming the market by 20.67% annually. With a current market capitalization of $7.52 billion, a $1000 investment made five years ago would now be worth $3,791.86.

powered bylight_fuzz_icon
46218233

*this image is generated using AI for illustrative purposes only.

Hims & Hers Health has generated significant shareholder value over the last half-decade, outperforming the market by 20.67% on an annualized basis with an average annual return of 31.83%. The company currently holds a market capitalization of $7.52 billion. This performance highlights the impact of compounded returns on long-term equity growth.

Investment Growth Analysis

The substantial appreciation in share price is evident when analyzing hypothetical investment scenarios. Based on a current price of $32.50, a $1000 investment in Hims & Hers Health made five years ago would have grown considerably.

Investment Period Initial Investment Current Value Current Price
5 Years $1000 $3,791.86 $32.50

Key Performance Metrics

The company's ability to deliver consistent returns above the broader market underscores its growth trajectory during this period. The data illustrates how compounded returns can significantly enhance capital appreciation over time.

Can Hims & Hers sustain its 31.83% annualized return as the company matures and market competition intensifies?

What strategic initiatives or product expansions are likely to drive the next phase of growth beyond the initial five-year surge?

How might rising interest rates or economic headwinds impact the company's valuation and future capital appreciation?

like18
dislike

Hims & Hers CAO Irene Becklund to depart after seven years

1 min read     Updated on 18 Jul 2026, 01:55 AM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Hims & Hers Health, Inc. announced that Chief Accounting Officer Irene Becklund will depart the company on October 9, 2026, after more than seven years. CFO Yemi Okupe will assume the responsibilities of CAO in the interim while the company searches for a permanent successor. Becklund will serve as an advisor for several months to assist with the transition.

powered bylight_fuzz_icon
45865499

*this image is generated using AI for illustrative purposes only.

Hims & Hers Health, Inc. announced that Chief Accounting Officer Irene Becklund will depart the company on October 9, 2026, after more than seven years. CFO Yemi Okupe will assume the responsibilities of CAO in the interim while the company searches for a permanent successor. Becklund will serve as an advisor for several months to assist with the transition.

Becklund joined Hims & Hers in 2019 as the company’s first Controller. She played a pivotal role in building and scaling the company's financial reporting and public company infrastructure. During her tenure, she helped guide the company through significant milestones, including its IPO, strategic acquisitions, and international expansion.

"Irene has left an indelible mark on Hims & Hers as a trusted leader whose expertise and judgment have been integral to our growth as a company," said Okupe. "Over the last seven years, Irene has helped build and maintain the financial discipline, technical rigor, and high standards that define our organization today."

Leadership Transition Details

The company will conduct a search for Becklund's permanent successor. In the interim, Okupe will oversee the accounting function while continuing his role as CFO.

Role Incumbent Status
Chief Accounting Officer Irene Becklund Departing October 9, 2026
Chief Financial Officer Yemi Okupe Assuming interim CAO duties

What criteria will Hims & Hers prioritize when selecting a permanent successor to maintain financial discipline during continued expansion?

How will the dual role of CFO and interim CAO impact Yemi Okupe's ability to focus on strategic growth initiatives?

Will the departure of the CAO influence the company's timeline or approach to future strategic acquisitions?

like15
dislike

More News on Hims & Hers Health Inc

Must Read Next

Earnings

PC Jeweller Q1 Results: Consolidated Net Profit Rises to ₹2.22B YoY 1 min ago
no imag found
ideaForge Technology Q1 Results: Revenue Jumps to 684M Rupees YoY, Loss Narrows to 23M 1 min ago

Stocks

Lupin Receives US FDA Approval for Sodium Zirconium Cyclosilicate Oral Suspension 1 hr ago
no imag found
Lumax Auto Technologies Establishes New Manufacturing Facility for Intelligent Ambient Comfort Division 1 hr ago
Bharat Electronics Secures New Orders Valued at ₹541 Crore 1 hr ago